Literature DB >> 31206214

Dose and Duration of Aspirin Use to Reduce Incident Hepatocellular Carcinoma.

Naoto Fujiwara1,2, Amit G Singal1, Yujin Hoshida1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31206214      PMCID： PMC6885093          DOI： 10.1002/hep.30813

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.298


× No keyword cloud information.
  9 in total

1.  Aspirin and Cancer Prevention in the Elderly: Where Do We Go From Here?

Authors:  Andrew T Chan; John McNeil
Journal:  Gastroenterology       Date:  2018-12-04       Impact factor: 22.682

2.  Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012.

Authors:  Donna L White; Aaron P Thrift; Fasiha Kanwal; Jessica Davila; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2016-11-23       Impact factor: 22.682

3.  Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.

Authors:  Tracey G Simon; Hector Bonilla; Peng Yan; Raymond T Chung; Adeel A Butt
Journal:  Hepatology       Date:  2016-03-25       Impact factor: 17.425

4.  Trends and Patterns of Disparities in Cancer Mortality Among US Counties, 1980-2014.

Authors:  Ali H Mokdad; Laura Dwyer-Lindgren; Christina Fitzmaurice; Rebecca W Stubbs; Amelia Bertozzi-Villa; Chloe Morozoff; Raghid Charara; Christine Allen; Mohsen Naghavi; Christopher J L Murray
Journal:  JAMA       Date:  2017-01-24       Impact factor: 56.272

5.  Association Between Aspirin Use and Risk of Hepatocellular Carcinoma.

Authors:  Tracey G Simon; Yanan Ma; Jonas F Ludvigsson; Dawn Q Chong; Edward L Giovannucci; Charles S Fuchs; Jeffrey A Meyerhardt; Kathleen E Corey; Raymond T Chung; Xuehong Zhang; Andrew T Chan
Journal:  JAMA Oncol       Date:  2018-12-01       Impact factor: 31.777

6.  Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

Authors:  Adrian M Di Bisceglie; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; James E Everhart; Elizabeth C Wright; William M Lee; Anna S Lok; Herbert L Bonkovsky; Timothy R Morgan; Marc G Ghany; Chihiro Morishima; Kristin K Snow; Jules L Dienstag
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

7.  Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.

Authors:  D K Li; P Yan; A-B Abou-Samra; R T Chung; A A Butt
Journal:  Aliment Pharmacol Ther       Date:  2017-11-03       Impact factor: 8.171

8.  Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults.

Authors:  In Cheol Hwang; Jooyoung Chang; Kyuwoong Kim; Sang Min Park
Journal:  Sci Rep       Date:  2018-03-21       Impact factor: 4.379

Review 9.  Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.

Authors:  Naoto Fujiwara; Scott L Friedman; Nicolas Goossens; Yujin Hoshida
Journal:  J Hepatol       Date:  2017-10-06       Impact factor: 30.083
  9 in total
  1 in total

1.  Current Status of the Use of Statins and Aspirin in the Chemoprevention of Hepatocellular Carcinoma.

Authors:  Yujin Hoshida
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.